Rationale for the use of hepatoprotective agents in the treatment of psoriasis
- Authors: Denisova E.1,2, Dvoryankova E.2, Denieva M.3, Sobolev V.2, Korsunskaya I.1,2
-
Affiliations:
- Moscow Research-and-Practical Center for Dermatovenereology and Cosmetology
- Center for Theoretical Problems of Physicochemical Pharmacology
- Republican Dermatovenereology Dispensary
- Issue: Vol 29, No 9 (2018)
- Pages: 85-88
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/117405
- DOI: https://doi.org/10.29296/25877305-2018-09-20
- ID: 117405
Cite item
Abstract
Current studies indicate comorbidity of psoriasis and various hepatobiliary disorders. Concurrence of psoriasis and non-alcoholic fatty liver disease is most frequently encountered. The paper describes common components in the pathogenesis of these diseases, which is one of the reasons for incorporating hepatoprotective agents in the combination therapy of psoriasis. The authors investigation demonstrates the advantage of a drug containing essential phospholipids and glycyrrhizic acid over conventional therapy with hepatoprotective drugs.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
E. Denisova
Moscow Research-and-Practical Center for Dermatovenereology and Cosmetology; Center for Theoretical Problems of Physicochemical PharmacologyCandidate of Medical Sciences
E. Dvoryankova
Center for Theoretical Problems of Physicochemical Pharmacology
M. Denieva
Republican Dermatovenereology DispensaryCandidate of Medical Sciences3; V
V. Sobolev
Center for Theoretical Problems of Physicochemical PharmacologyProfessor
I. Korsunskaya
Moscow Research-and-Practical Center for Dermatovenereology and Cosmetology; Center for Theoretical Problems of Physicochemical Pharmacology
References
- Олисова О.Ю. Псориаз: эпидемиология, патогенез, клиника, лечение // Дерматология. - 2010; 4: 3-8.
- Саутин М. Е., Соболева А.Г., Золотаренко А.Д. и др. Экспрессия MMP-2 и MMP-9 при псориазе и атеросклерозе // Рос. журн. кожн. и венерич. болезней. - 2013; 1: 27-9.
- Галиева Н.В., Головатенко-Абрамов П.К., Нестерова А.П. и др. Биоинформационный анализ молекулярно-генетических процессов при псориазе и болезни Крона // Соврем. проблемы дерматовенерол., иммунол. и врачебной косметол. - 2012; 3: 12-9.
- Kalb R., Strober В., Weinstein G. et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference // J. Am. Acaddermatol. -2009; 60 (5): 824-37.
- Lindsay K., Fraser A., Layton A. et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy // Rheumatology (Oxford). - 2009; 48 (5): 569-72.
- Загритдинова Р.М., Филимонов М.А., Трусов В.В. и др. Функциональные нарушения гепатобилиарной системы у больных псориазом и возможности их коррекции // Вестн. дерматол. и венерол. - 2006; 3: 11-4.
- Яковенко Г.Т., Корсунская И.М., Кривощапов Л.Г. Адеметионин в комплексной терапии псориаза // Клин. дерматол. и венерол. - 2013; 6: 59-62.
- Pietrzak D., Pietrzak A., Krasowska D. et al. Digestive system in psoriasis: an update // Arch. Dermatol. Res. - 2017; 309 (9): 679-93. doi: 10.1007/s00403-017-1775-7.
- Gisondi P., Targher G., Zoppini G. et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis // J. Hepatol. - 2009; 51: 758-64. doi: 10.1016/j.jhep.2009.04.020.
- Loria P., Carulli L., Bertolotti M. et al. Endocrine and liver interaction: the role of endocrine pathways in NASH // Nat. Rev Gastroenterol. Hepatol. - 2009; 6 (4): 236-47.
- Mantovani A., Gisondi P., Lonardo A. et al. Relationship between NonAlcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? // Int. J. Mol. Sci. - 2016; 17 (2): 217.
- Hardwick R., Clarke J., Lake A. et al. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis // Toxicol. Sci. - 2014; 142 (1): 45-55.
- Денисова Е.В., Дворянкова Е.В., Плиева К.Т. и др. Патологии гепатоби-лиарной системы у больных псориазом // Эффективная фармакотерапия. Дерматология и косметология. - 2018; 1: 26-30.
Supplementary files
![](/img/style/loading.gif)